India Market Research Report :PharmaFocus - Biomarkers in Alzheimer

Report: PharmaFocus - Biomarkers in Alzheimer

Category: Healthcare

www.researchonindia.com

http://www.researchonindia.com/


http://bit.ly/market_research_alzheimer-pharmafocus-biamarkers


• Publish date: 30th June, 2013

• Geographic coverage: Global

• Price for Single User License: USD 3,995

• Price for Site License: USD 7,990

• Price for Global User License: USD 11,985

• Delivery Time: Within 1 business day

• Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google

Wallet, PayPal

Report Details





• Amyloid-based biomarkers and amyloid PET ligands are the furthest

developed biomarkers for Alzheimer's Disease (AD) and although

they have immense value in diagnosis and drug discovery, there is a

remaining need for biomarkers of other pathological processes

• There is a great need for simple inexpensive biomarker assays that

can be implemented as diagnostic screens for AD and numerous

blood-based biomarker assays in pipeline are aiming to target this

• Government regulations will play a major role in biomarker

development, clinical market access and use in drug discovery both

in the US and in the EU

Report Insights





• Overview of AD, including disease etiology and patho-physiology and

how these inform biomarker targets

• Overview of AD biomarkers and major classes of biomarkers

• Different potential roles of biomarkers in clinical use and drug

development

• Key topics covered include amyloid biomarkers, tau biomarkers, and

other molecular biomarkers for AD in development with product

profiles for marketed as well as promising pipeline assays

• Functional and structural imaging biomarkers for AD

Report Coverage





• Analysis of the unmet needs, and opportunities within the AD

biomarker arena

• Drivers and barriers impacting the AD biomarker market

• Insightful review of the regulatory considerations impacting

biomarker development, market access and use in clinical drug

development

Report Coverage (Continued)





• Develop and design your in-licensing and out-licensing strategies

through a review of pipeline products and technologies, and by

identifying the companies with the most robust pipeline

• Develop business strategies by understanding the factors shaping

and driving AD biomarker development and market adoption

• Drive revenues by understanding the key trends, innovative products

and technologies, and companies likely to impact the AD biomarker

market in future

• Organize sales and marketing efforts by identifying the market

categories and segments that present maximum opportunities for

consolidations, investments and strategic partnerships

Report Benefits





• Introduction

• Alzheimer's disease

• AD biomarkers

• Unmet needs assessment

• AD biomarkers market drivers and barriers

• Amyloid beta biomarkers

• Tau-related biomarkers

• Beyond amyloid and tau: other molecular AD biomarkers in

development

Table of Contents





• Functional brain imaging biomarkers

• Structural brain imaging biomarkers

• Regulatory considerations impacting AD biomarkers

• Outlook and opportunities for AD biomarkers

• Appendix

Table of Contents (Continued)





Tables:

• Biomarker Unmet Needs - Current Level of Attainment • AD Biomarkers - Market Drivers and Barriers (2013) • AD - Amyloid-Targeting Phase III Pipeline (2013) • AD - Amyloid-Targeting Phase II Pipeline (2013) • A Biomarkers by Stage of Development (2013) • SWOT Analysis of Amyloid PET Imaging in AD (2013) • Product Profile of Amyvid (2013) • SWOT Analysis of Amyvid (2013) • Product Profile of [18F] Flutemetamol (2013) • SWOT Analysis of [18F] Flutemetamol (2013) • Product Profile of [18F] Florbetaben (2013) • SWOT Analysis of [18F] Florbetaben (2013) • Product Profile of NAV4694 (2013) • SWOT Analysis of NAV4694 (2013)

List of Tables and Figures





• Characteristics of ELISA and xMAP Immunoassay Platforms for the Measurement of CSF Biomarkers in AD

• SWOT Analysis of CSF-Based Amyloid Tests (2013) • Product Profile of INNOTEST -Amyloid1-42 (2013) • SWOT Analysis of INNOTEST -Amyloid1-42 (2013) • Product Profile of INNO-BIA AlzBio3 (2013) • SWOT Analysis of INNO-BIA AlzBio3 (2013) • Product Profile of EP-AD Diagnostic CSF Test (2013) • SWOT Analysis of EP-AD Diagnostic CSF Test (2013) • Product Profile of Abtest (2013) • SWOT Analysis of Abtest (2013) • Product Profile of SAPPHIRE II Eye Test (2013) • SWOT Analysis of SAPPHIRE II Eye Test (2013) • AD, Tau-Targeting Therapies, Phase III Pipeline (2013) • AD, Tau-Targeting Therapies, Phase II Pipeline (2013) • AD, Tau-Targeting Therapies, Phase I Pipeline (2013)


List of Tables and Figures (Continued)




• Tau Biomarkers by Stage of Development (2013) • SWOT Analysis of CSF-based Tau Assays (2013) • Product Profile of INNOTEST hTau Ag (2013) • SWOT Analysis of INNOTEST hTau Ag (2013) • Product Profile of INNOTEST PHOSPHO-TAU(181P) (2013) • SWOT Analysis of INNOTEST PHOSPHO-TAU(181P) (2013) • SWOT Analysis of Tau PET Imaging in AD (2013) • Potential Biomarkers of AD (2013) • Product Profile of Alzheimers CSF 16-Plex Assay (2013) • SWOT Analysis of Alzheimers CSF 16-Plex Assay (2013) • Product Profile of AclarusDx (2013) • SWOT Analysis of AclarusDx (2013) • Product Profile of ADpredict Screening Test (2013) • SWOT Analysis of ADpredict Screening Test (2013) • Product Profile of Alzheimers Plasma 9-Plex Assay (2013) • SWOT Analysis of Alzheimers Plasma 9-Plex Assay (2013)






• Product Profile of Adtect (2013) • SWOT Analysis of Adtect (2013) • Product Profile of MCItect (2013) • SWOT Analysis of MCItect (2013) • Product Profile of LymPro Test (2013) • SWOT Analysis of LymPro Test (2013) • Functional Brain Imaging Biomarkers by Stage of Development (2013) • SWOT Analysis of FDG- PET Imaging in AD (2013) • SWOT Analysis of FMRI Biomarkers in AD (2013) • Structural Brain Imaging Biomarkers by Stage of Development (2013) • SWOT Analysis of MRI Hippocampal Volumetry (2013) • Features of an Early-AD Therapy Clinical Trial (2013) • Summary of the FDA Guidance for Drug Development in Early AD (2013) • Biomarker Use in Ongoing AD Drug Clinical Trials (2013)






Figures:

• The Continuum of Alzheimers Disease • Atrophy of the Brain in Alzheimers Disease • Key Pathological Features in Alzheimers Disease • Non-Amyloidogenic Metabolism of APP • Amyloidogenic Metabolism of APP • Neurofibrillary Tangles • Oxidative Damage due to Free Radicals • Biomarkers in Drug Discovery • AD Biomarker Tests by Pathophysiology • Dynamic Changes in Alzheimers Disease Biomarkers






Interested in this report?

About Us Research on India (ROI) is a leading source for market research on various sectors in India and offers premium research content from worldwide publishers of market research reports

For further information, get in touch with us:

E-mail: [email protected] Call: International: +91 (22) 4098 7600

Industry Segments

Automotive & Transport Consumer goods Agriculture

Food and Beverage Energy and Utilities Public Sector

Manufacturing & Construction Healthcare Media & Entertainment

IT, Telecom & Electronics Services Others

To view more details regarding this premium market research report, Please click here


https://www.facebook.com/researchonindia

https://twitter.com/ResearchOnIndia

http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

http://blog.researchonindia.com/


Documents

India Market Research Report :PharmaFocus - Biomarkers in Alzheimer